Understanding the association between endothelial dysfunction and left ventricle diastolic dysfunction in development

Livija Sušić1, Lana Maričić2, Josip Vincelj3

  • 1Department of Internal Medicine, Osijek-Baranja County Health Center, Osijek, Croatia and Josip Juraj Strossmayer University of Osijek, Faculty of Medicine, Osijek, Croatia. livija.susic@gmail.com.

Insights

Cardiovascular diseases are a leading cause of death. New research highlights endothelial dysfunction as a key factor in conditions like INOCA and HFpEF, especially in younger populations and women, necessitating improved risk assessment methods.

Area of Science:

  • Cardiology
  • Biomarker Research

Background:

  • Cardiovascular diseases (CVDs) remain the leading global cause of mortality.
  • Historically, CVDs primarily affected middle-aged men via obstructive coronary artery disease (CAD).
  • Recent trends show increased incidence of ischemia with non-obstructive coronary arteries (INOCA) and heart failure with preserved ejection fraction (HFpEF), particularly in women and young adults.

Purpose of the Study:

  • To address the limitations of conventional risk assessment in emerging CVD patient groups.
  • To explore the role of endothelial dysfunction (ED) in INOCA and HFpEF.
  • To investigate the potential of plasma biomarkers for early detection and risk stratification.

Main Methods:

  • Review of current literature on INOCA and HFpEF pathophysiology.
  • Analysis of the role of endothelial dysfunction (ED) and left ventricular diastolic dysfunction (LVDD).
  • Exploration of plasma biomarkers, including endothelial dysfunction markers and natriuretic peptides (NPs).

Main Results:

  • Endothelial dysfunction (ED) is identified as a common underlying factor in INOCA and HFpEF.
  • Conventional risk assessment tools are insufficient for newer patient demographics experiencing these conditions.
  • Plasma biomarkers show promise for improved cardiovascular risk assessment.

Conclusions:

  • Endothelial dysfunction (ED) is a critical pathophysiological link between INOCA and HFpEF.
  • There is a need for novel diagnostic and risk assessment strategies for these conditions.
  • Investigated plasma biomarkers may offer future potential for early detection and management of cardiovascular risk.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
123
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
175
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
116
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
558
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
101